Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



News VIVUS Investors Need to Watch

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

The obesity market continues to be one of the hottest therapeutic areas in health care today. Arena Pharmaceuticals  (Nasdaq: ARNA  ) will soon launch its weight loss drug, Belviq, and VIVUS' (Nasdaq: VVUS  ) drug Qsymia is already available to patients through the Qsymia Home Delivery Network. CVS Caremark (NYSE: CVS  ) , Walgreen (NYSE: WAG  ) , and Express Scripts (Nasdaq: ESRX  ) are all part of the network, and patients currently receive their medication through the mail.

Today, VIVUS announced that it submitted a change to its Qsymia Risk Evaluation and Mitigation Strategy, or REMS, that could soon see prescriptions of the drug filled in retail pharmacies, too. In the following video, health care analysts Max Macaluso and David Williamson discuss the potential benefits of having more distribution channels if this application is successful.

VIVUS' most direct competition in this space is Arena Pharmaceuticals. Both companies gained FDA approval for their respective drugs at around the same time, and, while the future looks bright for Arena, there are still plenty of obstacles ahead. In our premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Click here now to learn more.

Max Macaluso, Ph.D. and David Williamson hold no positions in the stocks mentioned above. The Motley Fool owns shares of Express Scripts. Motley Fool newsletter services recommend Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 17, 2012, at 4:30 PM, kthor wrote:

    if you can't get the EU to approve of your drugs, your not worthy enough!

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2062388, ~/Articles/ArticleHandler.aspx, 10/24/2016 4:19:51 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,223.03 77.32 0.43%
S&P 500 2,151.33 10.17 0.47%
NASD 5,309.83 52.43 1.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 4:00 PM
ARNA $1.59 Up +0.02 +1.27%
Arena Pharmaceutic… CAPS Rating: **
CVS $88.00 Up +0.59 +0.67%
CVS Health CAPS Rating: ****
ESRX $69.80 Up +0.19 +0.27%
Express Scripts CAPS Rating: *****
VVUS $1.12 Up +0.02 +1.82%
VIVUS CAPS Rating: **
WBA $83.11 Up +1.54 +1.89%
Walgreens Boots Al… CAPS Rating: ****